Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 408

1.

End-of-life care in patients with advanced heart failure.

Diamant MJ, Keshmiri H, Toma M.

Curr Opin Cardiol. 2020 Mar;35(2):156-161. doi: 10.1097/HCO.0000000000000712.

PMID:
31833961
2.

Should We Be Using Sex-Specific Heart Failure Risk Scores?

Diamant MJ, Toma M.

Can J Cardiol. 2020 Jan;36(1):11-12. doi: 10.1016/j.cjca.2019.10.001. Epub 2019 Oct 8. No abstract available.

PMID:
31787437
3.

Medical therapy doses at hospital discharge in patients with existing and de novo heart failure.

Diamant MJ, Virani SA, MacKenzie WJ, Ignaszewski A, Toma M, Hawkins NM.

ESC Heart Fail. 2019 Aug;6(4):774-783. doi: 10.1002/ehf2.12454. Epub 2019 Jun 20.

4.

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.

Muskiet MHA, Bunck MC, Heine RJ, Cornér A, Yki-Järvinen H, Eliasson B, Joles JA, Diamant M, Tonneijck L, van Raalte DH.

Diabetes Res Clin Pract. 2019 Jul;153:14-22. doi: 10.1016/j.diabres.2019.05.001. Epub 2019 May 9.

PMID:
31078666
5.

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050.

Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, Ter Wee PM, Diamant M, Joles JA, van Raalte DH.

Diabetes Care. 2019 Mar;42(3):494. doi: 10.2337/dc19-er03. Epub 2019 Jan 23. No abstract available.

6.

The presence of cerebral white matter lesions and lower skin microvascular perfusion predicts lower cognitive performance in type 1 diabetes patients with retinopathy but not in healthy controls-A longitudinal study.

Emanuel AL, van Duinkerken E, Wattjes MP, Klein M, Barkhof F, Snoek FJ, Diamant M, Eringa EC, IJzerman RG, Serné EH.

Microcirculation. 2019 Apr;26(3):e12530. doi: 10.1111/micc.12530. Epub 2019 Feb 22.

7.

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.

Tonneijck L, Muskiet MHA, Blijdorp CJ, Smits MM, Twisk JW, Kramer MHH, Danser AHJ, Diamant M, Joles JA, Hoorn EJ, van Raalte DH.

Am J Physiol Renal Physiol. 2019 Feb 1;316(2):F231-F240. doi: 10.1152/ajprenal.00432.2018. Epub 2018 Oct 24.

8.

Influence of prednisolone on parameters of de novo lipogenesis and indices for stearoyl-CoA- and Δ6- desaturase activity in healthy males: A Post-hoc analysis of a randomized, placebo-controlled, double-blind trial.

Pranger IG, van Raalte DH, Brands M, Muskiet MHA, Kema IP, Serlie MJ, Diamant M, Bakker SJL, Muskiet FAJ.

Prostaglandins Leukot Essent Fatty Acids. 2018 May;132:8-15. doi: 10.1016/j.plefa.2018.03.009. Epub 2018 Apr 3.

PMID:
29735021
9.

Accelerated executive functions decline and gray matter structural changes in middle-aged type 1 diabetes mellitus patients with proliferative retinopathy.

van Duinkerken E, Steenwijk MD, Klein M, Barkhof F, Mograbi DC, Diamant M, Snoek FJ, Ijzerman RG.

J Diabetes. 2018 Nov;10(11):835-846. doi: 10.1111/1753-0407.12773. Epub 2018 May 30.

PMID:
29665283
10.

Cortical and subcortical gray matter structural alterations in normoglycemic obese and type 2 diabetes patients: relationship with adiposity, glucose, and insulin.

Bernardes G, IJzerman RG, Ten Kulve JS, Barkhof F, Diamant M, Veltman DJ, Landeira-Fernandez J, van Bloemendaal L, van Duinkerken E.

Metab Brain Dis. 2018 Aug;33(4):1211-1222. doi: 10.1007/s11011-018-0223-5. Epub 2018 Apr 13.

11.

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.

Tonneijck L, Muskiet MHA, Smits MM, Bjornstad P, Kramer MHH, Diamant M, Hoorn EJ, Joles JA, van Raalte DH.

Diabetes Obes Metab. 2018 May;20(5):1235-1245. doi: 10.1111/dom.13223. Epub 2018 Feb 20.

12.

Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues.

Ten Kulve JS, Veltman DJ, Gerdes VEA, van Bloemendaal L, Barkhof F, Deacon CF, Holst JJ, Drent ML, Diamant M, IJzerman RG.

Diabetes Care. 2017 Nov;40(11):1522-1529. doi: 10.2337/dc16-2113.

PMID:
29025878
13.

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

Vendrik KEW, Tonneijck L, Muskiet MHA, Kramer MHH, Pouwels PJW, Pieters-van den Bos IC, Diamant M, Cahen DL, van Raalte DH, Smits MM.

Pancreas. 2017 Oct;46(9):e75-e76. doi: 10.1097/MPA.0000000000000893. No abstract available.

PMID:
28902800
14.

Continuous Glucose Monitoring in Patients with Type 1 Diabetes and Impaired Awareness of Hypoglycemia: Also Effective in Patients with Psychological Distress?

van Beers CAJ, de Wit M, Kleijer SJ, Geelhoed-Duijvestijn PH, DeVries JH, Kramer MHH, Diamant M, Serné EH, Snoek FJ.

Diabetes Technol Ther. 2017 Oct;19(10):595-599. doi: 10.1089/dia.2017.0141. Epub 2017 Aug 24.

PMID:
28836833
15.

Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.

Lipš M, Mráz M, Kloučková J, Kopecký P, Dobiáš M, Křížová J, Lindner J, Diamant M, Haluzík M.

Diabetes Obes Metab. 2017 Dec;19(12):1818-1822. doi: 10.1111/dom.13029. Epub 2017 Jul 31.

PMID:
28581209
16.

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.

Chen WJY, Diamant M, de Boer K, Harms HJ, Robbers LFHJ, van Rossum AC, Kramer MHH, Lammertsma AA, Knaapen P.

Cardiovasc Diabetol. 2017 May 19;16(1):67. doi: 10.1186/s12933-017-0549-z.

17.

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.

Tonneijck L, Muskiet MHA, Smits MM, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH.

Diabetes Obes Metab. 2017 Dec;19(12):1669-1680. doi: 10.1111/dom.12985. Epub 2017 Jul 25.

PMID:
28449402
18.

Altered eigenvector centrality is related to local resting-state network functional connectivity in patients with longstanding type 1 diabetes mellitus.

van Duinkerken E, Schoonheim MM, IJzerman RG, Moll AC, Landeira-Fernandez J, Klein M, Diamant M, Snoek FJ, Barkhof F, Wink AM.

Hum Brain Mapp. 2017 Jul;38(7):3623-3636. doi: 10.1002/hbm.23617. Epub 2017 Apr 21.

PMID:
28429383
19.

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, van Raalte DH.

Diabetes Res Clin Pract. 2017 Feb;124:1-10. doi: 10.1016/j.diabres.2016.12.011. Epub 2016 Dec 27.

PMID:
28086201
20.

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Pieters-van den Bos IC, Vendrik KE, Hoekstra T, Bruno MJ, Diamant M, van Raalte DH, Cahen DL.

Diabetes Care. 2017 Mar;40(3):301-308. doi: 10.2337/dc16-0836. Epub 2016 Dec 20.

PMID:
27998910
21.

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.

van Beers CA, DeVries JH, Kleijer SJ, Smits MM, Geelhoed-Duijvestijn PH, Kramer MH, Diamant M, Snoek FJ, Serné EH.

Lancet Diabetes Endocrinol. 2016 Nov;4(11):893-902. doi: 10.1016/S2213-8587(16)30193-0. Epub 2016 Sep 15.

PMID:
27641781
22.

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, van Raalte DH.

Eur J Endocrinol. 2017 Jan;176(1):77-86. Epub 2016 Oct 24.

PMID:
27777261
23.

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Pouwels PJ, Pieters-van den Bos IC, Hoekstra T, Diamant M, van Raalte DH, Cahen DL.

Diabetologia. 2016 Dec;59(12):2588-2593. Epub 2016 Sep 15.

24.

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

Tonneijck L, Smits MM, Muskiet MH, Hoekstra T, Kramer MH, Danser AH, Ter Wee PM, Diamant M, Joles JA, van Raalte DH.

Diabetes Care. 2016 Nov;39(11):2042-2050. Epub 2016 Sep 1. Erratum in: Diabetes Care. 2019 Mar;42(3):494.

PMID:
27585605
25.

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Serné EH, van Raalte DH.

Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2125-32. doi: 10.1161/ATVBAHA.116.307930. Epub 2016 Aug 25.

PMID:
27562916
26.

Smoking Is Associated with an Increased Risk for Surgery in Diverticulitis: A Case Control Study.

Diamant MJ, Schaffer S, Coward S, Kuenzig ME, Hubbard J, Eksteen B, Heitman S, Panaccione R, Ghosh S, Kaplan GG.

PLoS One. 2016 Jul 28;11(7):e0153871. doi: 10.1371/journal.pone.0153871. eCollection 2016.

27.

Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.

van Raalte DH, Bunck MC, Smits MM, Hoekstra T, Cornér A, Diamant M, Eliasson B, Marja-RiittaTaskinen, Heine RJ, Smith U, HanneleYki-Järvinen, Mari A.

Eur J Endocrinol. 2016 Oct;175(4):345-52. doi: 10.1530/EJE-16-0286. Epub 2016 Jul 27.

PMID:
27466218
28.

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Nieuwdorp M, Groen AK, Cahen DL, van Raalte DH.

Diabetes Obes Metab. 2016 Dec;18(12):1217-1225. doi: 10.1111/dom.12748. Epub 2016 Aug 30.

29.

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.

Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V; LixiLan PoC Study Group.

Diabetes Care. 2016 Sep;39(9):1579-86. doi: 10.2337/dc16-0046. Epub 2016 Jun 9.

30.

Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.

Smits MM, Tonneijck L, Muskiet MH, Diamant M, Kramer MH, Cahen DL, van Raalte DH.

Diabet Med. 2017 Apr;34(4):591-592. doi: 10.1111/dme.13160. No abstract available.

31.

Retinal blood flow is increased in type 1 diabetes mellitus patients with advanced stages of retinopathy.

Nguyen HT, van Duinkerken E, Verbraak FD, Polak BC, Ringens PJ, Diamant M, Moll AC.

BMC Endocr Disord. 2016 May 26;16(1):25. doi: 10.1186/s12902-016-0105-y.

32.

Subgenual Cingulate Cortex Functional Connectivity in Relation to Depressive Symptoms and Cognitive Functioning in Type 1 Diabetes Mellitus Patients.

van Duinkerken E, Ryan CM, Schoonheim MM, Barkhof F, Klein M, Moll AC, Diamant M, IJzerman RG, Snoek FJ.

Psychosom Med. 2016 Jul-Aug;78(6):740-9. doi: 10.1097/PSY.0000000000000335.

PMID:
27136504
33.

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.

Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH.

Diabetologia. 2016 Jul;59(7):1412-1421. doi: 10.1007/s00125-016-3938-z. Epub 2016 Apr 1.

34.

Altered Skeletal Muscle Fatty Acid Handling in Subjects with Impaired Glucose Tolerance as Compared to Impaired Fasting Glucose.

Goossens GH, Moors CC, Jocken JW, van der Zijl NJ, Jans A, Konings E, Diamant M, Blaak EE.

Nutrients. 2016 Mar 14;8(3):164. doi: 10.3390/nu8030164.

35.

Alterations in white matter volume and integrity in obesity and type 2 diabetes.

van Bloemendaal L, Ijzerman RG, Ten Kulve JS, Barkhof F, Diamant M, Veltman DJ, van Duinkerken E.

Metab Brain Dis. 2016 Jun;31(3):621-9. doi: 10.1007/s11011-016-9792-3. Epub 2016 Jan 27.

36.

Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.

Ten Kulve JS, Veltman DJ, van Bloemendaal L, Groot PF, Ruhé HG, Barkhof F, Diamant M, Ijzerman RG.

J Endocrinol. 2016 Apr;229(1):1-12. doi: 10.1530/JOE-15-0461. Epub 2016 Jan 14.

PMID:
26769912
37.

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.

Smits MM, Bunck MC, Diamant M, Corner A, Eliasson B, Heine RJ, Smith U, Yki-Järvinen H, van Raalte DH.

Diabetes Care. 2016 Mar;39(3):e42-3. doi: 10.2337/dc15-2489. Epub 2015 Dec 30. No abstract available.

PMID:
26721816
38.

Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy.

van Duinkerken E, Ijzerman RG, Klein M, Moll AC, Snoek FJ, Scheltens P, Pouwels PJ, Barkhof F, Diamant M, Tijms BM.

Hum Brain Mapp. 2016 Mar;37(3):1194-208. doi: 10.1002/hbm.23096. Epub 2015 Dec 23.

PMID:
26700243
39.

Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients.

Ten Kulve JS, van Bloemendaal L, Balesar R, IJzerman RG, Swaab DF, Diamant M, la Fleur SE, Alkemade A.

J Clin Endocrinol Metab. 2016 May;101(5):2122-9. doi: 10.1210/jc.2015-3291. Epub 2015 Dec 16.

PMID:
26672638
40.

Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.

Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Diamant M, Pieters-van den Bos IC, van Raalte DH, Cahen DL.

Diabetes Obes Metab. 2016 Mar;18(3):281-8. doi: 10.1111/dom.12612. Epub 2016 Jan 13.

PMID:
26640129
41.

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.

Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Diamant M, Joles JA, van Raalte DH.

Diabetes Obes Metab. 2016 Feb;18(2):178-85. doi: 10.1111/dom.12601. Epub 2016 Jan 5.

PMID:
26636423
42.

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.

Smits MM, Muskiet MH, Tonneijck L, Hoekstra T, Kramer MH, Diamant M, van Raalte DH.

Br J Clin Pharmacol. 2016 Apr;81(4):613-20. doi: 10.1111/bcp.12843. Epub 2016 Jan 25.

43.

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Pieters IC, Cahen DL, Diamant M, van Raalte DH.

BMJ Open. 2015 Nov 19;5(11):e009579. doi: 10.1136/bmjopen-2015-009579.

44.

Lower birth weight is associated with alterations in dietary intake in adolescents independent of genetic factors: A twin study.

Doornweerd S, IJzerman RG, Weijs PJ, Diamant M, de Geus EJ, Boomsma DI.

Clin Nutr. 2017 Feb;36(1):179-185. doi: 10.1016/j.clnu.2015.10.012. Epub 2015 Oct 30.

PMID:
26575849
45.

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.

ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Deacon CF, Holst JJ, Konrad RJ, Sloan JH, Drent ML, Diamant M, IJzerman RG.

Diabetologia. 2015 Dec;58(12):2688-98. doi: 10.1007/s00125-015-3754-x. Epub 2015 Sep 18.

46.

Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation.

van Bloemendaal L, Veltman DJ, ten Kulve JS, Drent ML, Barkhof F, Diamant M, IJzerman RG.

Obesity (Silver Spring). 2015 Oct;23(10):2075-82. doi: 10.1002/oby.21200. Epub 2015 Aug 31.

47.

Design and rationale of the IN CONTROL trial: the effects of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired awareness of hypoglycemia.

van Beers CA, Kleijer SJ, Serné EH, Geelhoed-Duijvestijn PH, Snoek FJ, Kramer MH, Diamant M.

BMC Endocr Disord. 2015 Aug 21;15:42. doi: 10.1186/s12902-015-0040-3.

49.

Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.

Ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Drent ML, Diamant M, IJzerman RG.

Diabetes Care. 2016 Feb;39(2):214-21. doi: 10.2337/dc15-0772. Epub 2015 Aug 17.

PMID:
26283736
50.

Palmitic acid increases pro-oxidant adaptor protein p66Shc expression and affects vascularization factors in angiogenic mononuclear cells: Action of resveratrol.

Favre J, Yildirim C, Leyen TA, Chen WJ, van Genugten RE, van Golen LW, Garcia-Vallejo JJ, Musters R, Baggen J, Fontijn R, van der Pouw Kraan T, Serné E, Koolwijk P, Diamant M, Horrevoets AJ.

Vascul Pharmacol. 2015 Dec;75:7-18. doi: 10.1016/j.vph.2015.08.003. Epub 2015 Aug 5.

PMID:
26254104

Supplemental Content

Loading ...
Support Center